Peter E. Williams
Beerse, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity.
Journal: Nature communications
Published: June 27, 2024
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Journal: The New England journal of medicine
Published: March 05, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Journal: The New England journal of medicine
Published: March 05, 2020
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV.
Journal: AIDS research and human retroviruses
Published: May 31, 2019
Design, Formulation, and Evaluation of Novel Dissolving Microarray Patches Containing Rilpivirine for Intravaginal Delivery.
Journal: Advanced healthcare materials
Published: November 22, 2018
Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: July 11, 2018
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Journal: Lancet (London, England)
Published: June 02, 2017
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
Journal: The lancet. HIV
Published: March 02, 2016
Correction: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.
Journal: PLoS pathogens
Published: October 17, 2015
Formulation and pharmacology of long-acting rilpivirine.
Journal: Current opinion in HIV and AIDS
Published: June 08, 2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Journal: The Lancet. Infectious diseases
Published: May 14, 2015
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.
Journal: PLoS pathogens
Published: April 16, 2015
Last Updated: 09/26/2026